Investors

Investor FAQs

Investor FAQs

Show All
Who is Adicet Bio., Inc.'s transfer agent?
The transfer agent and registrar for the common stock of Adicet Bio, Inc. stock is

Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
(800) 962-4284
How do I transfer stock, change the address on my shareholder account, or replace a lost stock certificate?
To change the address on your shareholder account you must send both your old and new addresses to our transfer agent, Computershare Trust Company, N.A., 250 Royall Street, Canton, Massachusetts 02021.

To replace a lost stock certificate, contact our transfer agent, Computershare Trust Company, N.A.. The transfer agent can look up your records and make any necessary adjustments.
Does Adicet Bio., Inc. have a direct stock purchase plan?
Adicet Bio, Inc. does not have a direct stock purchase plan.
What exactly is a CVR?
CVR stands for contingent value right. This CVR will entitle holders to receive net proceeds of the commercialization, if any, received from a third party commercial partner of RTB101, the Company’s small molecule product candidate that is a potent inhibitor of target of rapamycin complex 1 (TORC1), for a COVID-19 related indication, with clinical data expected by the first quarter of 2021. If the Company does not enter into a commercial agreement with any such third party partner prior to September 30, 2021, or if the Company does enter into such commercial agreement, but does not receive any net proceeds pursuant to such commercial agreement, no payments will be made under the CVRs, and the CVRs will expire valueless.
Can I sell my CVR?
The CVRs are not transferable, except in certain limited circumstances as provided in the contingent value rights agreement, will not be certificated or evidenced by any instrument and will not be registered with the SEC or listed for trading on any exchange.
What are the tax consequences of receiving the CVRs?
The U.S. federal income tax treatment of the CVRs is unclear. There is no legal authority directly addressing the U.S. federal income tax treatment of the receipt of, and payments on, the CVRs, and there can be no assurance that the IRS, would not assert, or that a court would not sustain, a position that could result in adverse U.S. federal income tax consequences to holders of the CVRs. You should consult your own tax advisor as to the treatment of the payment that you may receive for the CVR. You should also read the disclosure in the registration statement on Form S-4 filed by the Company in connection with the merger under the heading “Material U.S. Federal Income Tax Consequences of the Receipt of CVRs” and also consult your personal tax advisor to determine the particular tax consequences to you of the merger.